Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -60.79% is 16% below its 5-year average of -52.22%, around the middle of its 5-year range (-117.97%–-28.43%).
As of the fiscal period ended Tuesday, June 30, 2026. 22.55% above its 12-month average of -78.49%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -60.79%.
RETURN ON EQUITY (ROE)
-60.79%
RETURN ON EQUITY (ROE) AVG TTM
-78.49%
RETURN ON EQUITY (ROE) AVG 3Y
-67.89%
RETURN ON EQUITY (ROE) AVG 5Y
-52.22%
RETURN ON EQUITY (ROE) AVG 10Y
-59.94%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+22.55%
CURRENT VS 3Y AVG
+10.46%
CURRENT VS 5Y AVG
-16.41%
CURRENT VS 10Y AVG
-1.43%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-44.71%
vs the sector median at left
Aclaris Therapeutics, Inc.
Market Cap
$521.64M
Return on Equity (ROE)
-60.79%
TTM Avg
-78.49%
3Y Avg
-67.89%
5Y Avg
-52.22%
Market Cap
$520.72M
Return on Equity (ROE)
-19.35%
TTM Avg
-58.07%
3Y Avg
-51.86%
5Y Avg
-46.32%
Market Cap
$524.04M
Return on Equity (ROE)
N/A
TTM Avg
44.05%
3Y Avg
44.05%
5Y Avg
44.05%
Market Cap
$523.62M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$513.70M
Return on Equity (ROE)
-99.83%
TTM Avg
118.83%
3Y Avg
8.21%
5Y Avg
-14.12%
Market Cap
$510.17M
Return on Equity (ROE)
-27.20%
TTM Avg
-44.25%
3Y Avg
-32.03%
5Y Avg
-24.61%
Market Cap
$535.16M
Return on Equity (ROE)
N/A
TTM Avg
91.17%
3Y Avg
180.92%
5Y Avg
76.31%
Market Cap
$509.10M
Return on Equity (ROE)
-37.94%
TTM Avg
-63.13%
3Y Avg
-60.30%
5Y Avg
-47.34%
Market Cap
$536.32M
Return on Equity (ROE)
N/A
TTM Avg
6.49%
3Y Avg
6.51%
5Y Avg
-75.00%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $521.64M | -60.79% | -78.49% | -67.89% | -52.22% |
| Altimmune, Inc. (ALT)vs › | $520.72M | -19.35% | -58.07% | -51.86% | -46.32% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $524.04M | N/A | 44.05% | 44.05% | 44.05% |
| Immix Biopharma, Inc. (IMMX)vs › | $523.62M | -17.44% | -97.25% | -87.77% | -77.06% |
| Crescent Biopharma, Inc. (CBIO)vs › | $513.70M | -99.83% | 118.83% | 8.21% | -14.12% |
| 908 Devices Inc. (MASS)vs › | $510.17M | -27.20% | -44.25% | -32.03% | -24.61% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $535.16M | N/A | 91.17% | 180.92% | 76.31% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.10M | -37.94% | -63.13% | -60.30% | -47.34% |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | 6.49% | 6.51% | -75.00% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $534.18M | -306.61% | -169.61% | -163.97% | -73.13% |
ROE
-60.8%
ROA
-42.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -60.79% |
| 2026-03-31 | -48.49% |
| 2025-12-31 | -62.98% |
| 2025-09-30 | -117.97% |
| 2025-06-30 | -102.21% |
| 2025-03-31 | -90.38% |
| 2024-12-31 | -84.90% |
| 2024-09-30 | -28.43% |
| 2024-06-30 | -43.85% |
| 2024-03-31 | -54.40% |
| 2023-12-31 | -56.29% |
| 2023-09-30 | -73.32% |
| 2023-06-30 | -58.59% |
| 2023-03-31 | -54.45% |
| 2022-12-31 | -43.98% |
| 2022-09-30 | -37.34% |
| 2022-06-30 | -35.32% |
| 2022-03-31 | -44.89% |
| 2021-12-31 | -46.04% |
| 2021-09-30 | -37.51% |
| 2021-06-30 | -30.26% |
| 2021-03-31 | -57.16% |
| 2020-12-31 | -135.50% |
| 2020-09-30 | -138.47% |
| 2020-06-30 | -204.79% |
| 2020-03-31 | -239.58% |
| 2019-12-31 | -230.80% |
| 2019-09-30 | -212.62% |
| 2019-06-30 | -115.67% |
| 2019-03-31 | -76.86% |
| 2018-12-31 | -61.70% |
| 2018-09-30 | -80.04% |
| 2018-06-30 | -58.88% |
| 2018-03-31 | -43.00% |
| 2017-12-31 | -30.42% |
| 2017-09-30 | -23.36% |
| 2017-06-30 | -29.48% |
| 2017-03-31 | -29.70% |
| 2016-12-31 | -28.37% |
| 2016-09-30 | -50.93% |
| 2016-06-30 | -45.72% |
| 2016-03-31 | -37.23% |
| 2015-12-31 | -22.23% |
| 2015-06-30 | -96.99% |
| 2015-03-31 | -62.59% |
